Ube Industries, Inc.

Sankyo Company, Limited

Daiichi Sankyo Company, Limited

Ube Corporation

Sanwa Kagaku Kenkyusho Co., Ltd.

Sanko Co., Ltd.

Tomio Kimura

Shigeru Ushiyama

Tetsushi Katsube

Noriaki Iwase

Shigeyuki Kono

Teruhiko Inoue

Yusuke Shiraishi

Masayuki Iwata

Atsuhiro Sugidachi

Masahiro Kojima

Makoto Okudo

Yoshimi Fujihara

Masaaki Ito

Akira Nakao

Ken-ichi Komori

Eiji Okanari

Yasuhiro Aga

Koji Ito

Masaaki Matoyama

Satoshi Umezaki

Kazumasa Aoki

Hiroshi Fujiwara

Nobuyuki Ohkawa

Yasunori Tsuzaki

Hiroshi Nishida

Hidetoshi Sunamoto

Tetsuo Kawaguchi

Yasunori Tokunaga

Sayaka Ogi

Takayoshi Nagasaki

Koji Suda

Kenji Nishikawa

Haruka Yamada

Noritada Iwamoto

Akishi Ninomiya

Hiroyoshi Kawada

Tetsuo Omata

Masaru Shinohara

Takashi Matsushita

Kazuhiro Onuma

Hirofumi Matsunaga

Keisuke Suzuki

Hiroyuki Koike

Toshio Kaneko

Shigeyoshi Nishino

Fumitoshi Asai

Mamoru Nakai

Masaaki Miyamoto

Shinichi Kurakata

Osamu Ando

Saori Kanai

Masaharu Hanai

Yasuo Noguchi

Tokio Ohshima

Akihiro Kawara

Masayuki Tanaka

Yasushi Takahashi

Naoki Tanaka

Motohisa Shimizu

Toshiyuki Konosu

Nobuyoshi Iwata

Keiichi Tabata

Takashi Kobayashi

Keiji Ueda

Yoshiaki Kuroki

Nobuhiko Shibakawa

Ryo Iwamura

Kenji Yoneda

Kazuhiko Tanzawa

Kentoku Gotanda

Hitoshi Ueno

Hiroyuki Setoguchi

Kaori Taniko

Keiji Matsunobu

Tomoko Kanda

Hiroto Akaza

Takashi Nishigaki

Yoshio Kaku

Hayato Nishiyama

Toshiyuki Miyazawa

Daisuke Kurumazuka

Isao Nakayama

Satoko Harada

Tokio Oshima

Toru Izuchi

Kanichi Nakamura

Morio Okabe

Takanori Yamazaki

Naoya Kinoshita

Shoujiro Miyazaki

Wataru Takasaki

Etsuro Itoh

Yoshimi Fujihara, Deceased

Shigeharu Anpeiji

Takashi Ikuta

Tatsuroh Kaneko

Yuuki Imura

The present invention provides a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, the two Rs each independently represents a Calkyl group, or are bonded together to form a Calkylene group, A represents a Caryl group (which may be a substituted Caryl group), Z represents a hydrogen atom or a Calkyl group (which may be a substituted Caryl group), or A and Z may be bonded to each other, with the group represented by Z—N-A forming a bicyclic fused heteroaryl group, which may be substituted, and R, R, and Reach independently represents a linear or branched Calkyl group that may be substituted.]

Dihydropyrrolopyrazole derivative

The present invention provides a compound of general formula (I) (wherein X is as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.

Substituted guanidine compounds

The present invention provides a compound that is highly safe and useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical composition containing the compound, a method for producing the compound, and the like. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein: Aand Aeach independently represent an inhibitor residue having at least one activity selected from an enteropeptidase inhibitory activity and a trypsin inhibitory activity; and Z represents a spacer that links Ato A] or a pharmaceutically acceptable salt thereof.

Double-headed protease inhibitor

The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a Calkyl group or the like; and R, Rand Reach independently represent an optionally substituted linear or branched Calkyl group. 

Substituted dihydropyrrolopyrazole derivative

The present invention provides a compound of general formula (I) (wherein, R, X, p and q are as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.

Substituted guanidine derivatives

A novel &#x3b1;-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided. A compound represented by the general formula (I) wherein A represents, a phenyl ring, a thiophene ring, or an isothiazole ring; Ris the same or different, and represents a halogen atom, or a C-Calkyl group; Rrepresents a hydrogen atom, or a C-Calkyl group; p represents an integer of 0 to 5; V represents CRwherein Rrepresents a hydrogen atom, an amino group, a nitro group, or a C-Calkoxy group, or V represents a nitrogen atom; and X represents a halogen atom, or a salt thereof.

Halogen-substituted heterocyclic compound

Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein Lis an optionally substituted Calkylene group or the like, Lis a single bond or the like, Lis a single bond or the like, R, R, and Rare each independently an optionally substituted Calkyl group or the like, Ris a hydrogen atom or the like, and Ris a hydrogen atom or the like.

Substituted dihydropyrrolopyrazole compound

The invention provides a novel &#x3b1;-halogen-substituted thiophene compound salt that has a potent LPA receptor antagonistic action and is useful as a medicament. The salt is represented by the general formula (I):  

Halogen-substituted heterocyclic compound salt

A novel &#x3b1;-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided.

The object of the present invention is to provide a compound having an antagonistic action against &#x3bc;-opioid receptors, which causes less side effects and thus is highly safe. A compound represented by the general formula (I), or a pharmacologically acceptable salt thereof:   

3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose

A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein,

Substituted acrylamide derivative and pharmaceutical composition comprising the same

It is an object of the present invention to provide a substituted propanamide derivative or a pharmacologically acceptable salt thereof that is useful as a prophylactic or therapeutic agent for a bone metabolic disease. The present invention relates to a pharmaceutical composition comprising a compound having General Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, Rrepresents a C-Caryl group that may be substituted by a group selected from Substituent Group &#x3b1;, for example; Rrepresents a C-Caryl group that may be substituted by a group selected from Substituent Group &#x3b1;, for example; and X represents a hydroxyl group or a C-Calkoxy group, for example].

Substituted propanamide derivative and pharmaceutical composition containing the same

A compound of formula (I) Wherein X, Y, ring A, ring B, l, m, R, R, Rand Rare as defined herein, to supress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-&#x3b1;, pharmacologically acceptable salts therefor, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.

Substituted cycloalkene derivative

Growing community of inventors

Tokyo, Japan

Tomio Kimura